Skip to content

Vaxcyte, Inc. PCVX Other Income (Expense)

Other Income (Expense) at other companies

Moderna logo
ModernaMRNA
-$18M-350%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$563M-760%

Segments

By segment

See full
Reportable Segment$25.23M-37.0%

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s other income (expense)?
Vaxcyte, Inc. (PCVX) reported other income (expense) of $25.23M in Q1 2026.
How has Vaxcyte, Inc.'s other income (expense) changed year-over-year?
Vaxcyte, Inc.'s other income (expense) decreased by 37.0% year-over-year, from $40.08M to $25.23M.
What is the long-term trend for Vaxcyte, Inc.'s other income (expense)?
Over 4 years (2021 to 2025), Vaxcyte, Inc.'s other income (expense) has grown at a 157.1% compound annual growth rate (CAGR), from $3.59M to $157.05M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.